Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS).

Phase 4

Completed

Conditions: Benign Prostatic Hyperplasia

Interventions: Drug: Placebo
Drug: Tadalafil
Drug: Alpha1 Blocker

First Posted Date: 2015-05-01

Last Posted Date: 2017-07-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 171

Registration Number: NCT02431754

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan

A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer

Phase 3

Completed

Conditions: Urothelial Carcinoma

Interventions: Drug: Docetaxel
Drug: Ramucirumab
Drug: Placebo

First Posted Date: 2015-04-24

Last Posted Date: 2023-08-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 530

Registration Number: NCT02426125

Locations: 🇺🇸
Inova Comprehensive Cancer Care & Research Institute, Fairfax, Virginia, United States
🇺🇸
Southeast Florida Hematology/Oncology, Fort Lauderdale, Florida, United States
🇺🇸
University of Maryland- Biological Sciences, Baltimore, Maryland, United States

and more 36 locations

A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma

Phase 1

Completed

Conditions: Hepatocellular Carcinoma Recurrent
Non-Small Cell Lung Cancer Recurrent
Solid Tumor

Interventions: Drug: Galunisertib
Drug: Nivolumab

First Posted Date: 2015-04-22

Last Posted Date: 2021-09-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 41

Registration Number: NCT02423343

Locations: 🇺🇸
H Lee Moffitt Cancer Center, Tampa, Florida, United States
🇪🇸
Hospital Regional Universitario de Málaga, Malaga, Spain
🇪🇸
Institut Catala d'Oncologia, Barcelona, Spain

and more 6 locations

A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain (DPNP)

Phase 4

Completed

Conditions: Diabetic Peripheral Neuropathic Pain

Interventions: Drug: Duloxetine
Drug: Pregabalin
Drug: Placebo

First Posted Date: 2015-04-16

Last Posted Date: 2019-09-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 304

Registration Number: NCT02417935

The Forteo Alendronate Comparator Trial

Phase 4

Completed

Conditions: Osteoporosis

Interventions: Drug: Teriparatide
Drug: Alendronate
Dietary Supplement: Calcium
Dietary Supplement: Vitamin D
Drug: Placebo-Oral
Drug: Placebo-SC

First Posted Date: 2015-04-14

Last Posted Date: 2015-04-14

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 203

Registration Number: NCT02416271

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico

A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung
Neoplasm Metastasis

Interventions: Drug: Necitumumab
Drug: Abemaciclib

First Posted Date: 2015-04-08

Last Posted Date: 2020-07-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 66

Registration Number: NCT02411591

Locations: 🇪🇸
Hospital Universitario Ramon y Cajal, Madrid, Spain
🇫🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician., Villejuif, France
🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

Phase 3

Active, not recruiting

Conditions: Metastatic Non-Small Cell Lung Cancer

Interventions: Drug: Placebo
Drug: Ramucirumab
Drug: Erlotinib
Drug: Gefitinib
Drug: Osimertinib

First Posted Date: 2015-04-08

Last Posted Date: 2025-01-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 545

Registration Number: NCT02411448

Locations: 🇺🇸
UCLA Hematology/Oncology - Santa Monica, Los Angeles, California, United States
🇺🇸
AHN Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
🇯🇵
Hyogo Prefectual Amagasaki General Medical Center, Amagashiki, Hyogo, Japan

and more 103 locations

A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer Metastatic

Interventions: Drug: LY3023414
Drug: Placebo
Drug: Enzalutamide

First Posted Date: 2015-04-02

Last Posted Date: 2021-05-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 142

Registration Number: NCT02407054

Locations: 🇺🇸
Sharp Memorial Hospital, San Diego, California, United States
🇺🇸
Fort Wayne Oncology & Hematology, Fort Wayne, Indiana, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States

and more 33 locations

Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents

Phase 3

Completed

Conditions: Hypoglycemia
Diabetes Mellitus

Interventions: Drug: Nasal Glucagon

First Posted Date: 2015-03-30

Last Posted Date: 2019-09-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 26

Registration Number: NCT02402933

Locations: 🇺🇸
Private Clinic, Baltimore, Maryland, United States
🇺🇸
New England Diabetes and Endocrinology Center (NEDEC), Waltham, Massachusetts, United States

A Study Of Galcanezumab In Participants With Episodic Cluster Headache

Phase 3

Completed

Conditions: Episodic Cluster Headache

Interventions: Drug: Placebo
Drug: Galcanezumab

First Posted Date: 2015-03-25

Last Posted Date: 2019-09-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 109

Registration Number: NCT02397473

Locations: 🇺🇸
New England Institute for Clinical Research, Stamford, Connecticut, United States
🇺🇸
Dent Neurological Institute, Amherst, New York, United States
🇺🇸
Mayo Clinic-Jacksonville, Jacksonville, Florida, United States

and more 21 locations

Home Terms & Conditions Privacy Policy